Clinical Trial Detail

NCT ID NCT03601897
Title A Safety, Tolerability and PK Study of Rebastinib in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Deciphera Pharmaceuticals LLC
Indications

Advanced Solid Tumor

Therapies

Paclitaxel + Rebastinib

Age Groups: senior adult

No variant requirements are available.